You may have noticed a change this week as we have debuted a fresh look for quotientsciences.com! 

Take 5 minutes to read a brief overview on some differences that you'll find as you navigate our new website.

We've given our site a modern look, with a faster and more mobile-friendly experience.

Speed and agility are pivotal to our brand promise, and we wanted to make sure to reflect this, not only in the services and programs we offer but in how we deliver information to you through our digital channels, starting with our website. 

In redesigning our website, we've paid close attention to where previous features impacted page speed. Additionally, a new content management system for our website offers us technical features that you can't outwardly see, but also enable us to deliver content that you're looking for, fast.

We've made design and technical improvements for greater attention to accessibility.

The concept of website accessibility means that websites and related tools or technologies are designed and developed so that people with disabilities can perceive, understand, navigate, and interact with them, contributing to a more diverse and inclusive web experience. In this redesign, we've made improvements to ensure that our website is more inclusive to use for all. Consistent size of and visibility of text, consistent use of descriptions on images, and adjustments to how our brand colors are applied were some of the steps made to give a more accessible experience. We recognize that technology and accessibility needs will continue to evolve, and aspire to implement future changes to keep up with those changes.

New content and easier access to understanding our capabilities added following insight gathered from our teams and customers. 

In our blog, you can search for a specific topic, subject matter expert, or Quotient Sciences location. Also, for those actively looking to join Quotient Sciences, or just wondering what life is like at our company for a future opportunity, you'll find careers- and location-related content in our blog and a redesigned experience on our careers page featuring new colleague stories. 

What hasn't changed: the continued emphasis on our mission of bringing molecules to cures, fast. 

We look forward to working with all of our customers, present and future, as partners in 2024. We value the important role that we have in supporting the development, testing, and manufacturing of new therapies that improve global health.

We hope you like the refreshed look and always welcome feedback. If you have any questions or comments for our team, please contact us at [email protected]. 
 

Dr. Sarah Stevens, former Vice President of Drug Development Sciences at Quotient Sciences, discusses our integrated approach to accelerating the development of poorly soluble compounds in a Drug Development & Delivery Special Feature article, "Improving Bioavailability & Solubility: Each Molecule Is Unique"

Solving bioavailability and solubil­ity challenges to support successful drug delivery is an ever-enduring challenge (and opportunity) for phar­maceutical formulation scientists. Along with well-established ap­proaches to improving each, there are many emerging platform technolo­gies, providing options in the toolbox. In many ways, though, availability of such formulation and process technol­ogy approaches does not present the primary barrier to improving universal solubility and bioavailability chal­lenges. Instead, a key challenge is the continued lack of predictive, clinically relevant models to guide formulation selection early enough in the develop­ment process – such that money and time are not unnecessarily expended, and avoidable risks not taken.

“With many examples of mislead­ing nonclinical and in vitro predictabil­ity out there, robust predictive models would afford the ability to understand and adapt for successful clinical out­comes from the outset,” says Dr. Sarah Stevens, Vice President of Drug Development Sciences at Quotient Sciences. “Quotient Sciences embod­ies science-led decision making, therefore not relying simply on poten­tially unreliable predictive models. A combination of unique development approaches provides the most expedi­tious means to improve potential bioavailability and solubility chal­lenges.”

Quotient, she says, deploys technologies such as particle size reduction, lipid-based formulation mechanisms, HME, SDD, etc., but more pertinently, drives early formula­tion selection by cutting through in­dustry silos and integrating across a range of capabilities to accelerate the drug development process.

Access the full article

Dr. Sarah Stevens, former VP of Drug Development Sciences at Quotient Sciences, discusses the recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities in a Drug Development & Delivery Special Feature Report, "Outsourcing Formulation Development & Manufacturing: Meeting Demand for Biologics & Specialty Drugs"

For the past decade, Quotient Sci­ences has created a delivery platform that integrates drug product and clin­ical testing activities to achieve pro­gram acceleration. To support this further, Quotient Sciences recently acquired Ar­cinova, the UK-based CDMO, be­cause of its expertise and capability in early-stage drug substance and bio­analysis work.

"We see a great opportunity for investing in and integrating drug sub­stance services into our existing drug product and clinical testing platform," says Sarah Stevens, Vice President of Drug Development Sciences, Quotient Sciences.

Drug substance manufacturing often sits on the critical path in early development with drug product man­ufacturing and clinical trial initiation routinely suffering from late API sup­ply, she says. As one of the major causes of project delays, it is important for biotech companies to work closely with API manufacturers early in the de­velopment process to ensure the drug substance is not only supplied on time but that potential formulation or downstream challenges have also been identified or flagged up front.

"The investment in this capability will enable the integration of drug substance, drug product, and clinical testing capabilities – all under one or­ganization with a single Project Man­agement function," she says.

Continue reading the article

Quotient Sciences announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. 

$15 million investment creates a center of excellence for early-phase formulation development and clinical trial manufacturing.

The Garnet Valley site will focus on developing small-molecule oral drug products, supporting development programs from the preclinical stage through to clinical proof-of-concept. Seamless scale-up to late-phase manufacturing and commercial product supply will continue at Quotient’s nearby Chelsea Parkway facility.

“Our new facility was built in response to increasing customer demand for our early-phase formulation development and clinical trial manufacturing services,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “The site was specifically designed to optimize our ability to work with highly potent and poorly soluble molecules that dominate the industry pipeline.”

“The facility also increases our capacity to provide integrated Translational Pharmaceutics® programs in the U.S., which deliver substantial benefits to customers including cost savings and reduced timelines to achieve proof-of-concept,” Egerton added.

The expanded formulation development, analytical, and manufacturing capabilities enable biotech and pharmaceutical companies to access Translational Pharmaceutics programs working under an investigational new drug (IND) application. This approach integrates real-time adaptive manufacturing and clinical research. Drug products manufactured at the Garnet Valley facility can be rapidly supplied to global patient trials and clinical pharmacology units, using tailored batch sizes and flexible dose adjustments.

Quotient Sciences has comprehensive drug product expertise spanning all dosage forms, from liquids to solids, immediate-release to modified-release, and solubilization technologies including spray-dried dispersions, micronized and lipidic formulations. The new facility is also designed to handle both potent and non-potent products, with six high-potency GMP manufacturing suites.

A further expansion of Quotient Sciences' formulation and manufacturing operations will be announced in the coming months. 

Nottingham, U.K., November 5th, 2018 – Quotient Sciences, a leading drug development services organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, U.K., facility. The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing, and significantly increased staffing levels.

“Our investment in Reading is in direct response to increasing client demand,” said Mark Egerton, CEO of Quotient Sciences. “With drug development expertise on both sides of the Atlantic, we are optimally positioned to serve our global client base. The Reading site can support customers with stand-alone formulation and clinical trial manufacturing services that can also be integrated into Translational Pharmaceutics^® programs.”

Activities at the 48,000-square-foot Reading facility are focused on small molecule drug products for oral and inhaled delivery spanning drug substance characterization, formulation development, and clinical trial manufacturing. The site routinely handles poorly soluble compounds and is equipped with a broad range of technologies including spray drying, hot melt extrusion, lipidic systems, and micronization.

Its capacity is bolstered by 13 GMP manufacturing suites to support traditional Phase I-III clinical trial manufacturing and Translational Pharmaceutics programs that integrate real-time adaptive manufacturing and clinical research. This flexible and nimble approach allows batch sizes to be tailored to the precise needs of a clinical trial. Drug products are rapidly supplied to global patient trials and clinical pharmacology units, delivering substantial benefits to customers including flexible dose adjustments, reductions in manufacturing costs, and shorter manufacturing lead times.

Quotient Sciences has more than 800 employees across six operating sites in the U.K. and U.S., serving a global customer base of more than 150 biotech and pharma clients.

Nottingham, U.K., December 3rd, 2018 - Quotient Sciences, a leading drug development services organization, has invested in additional spray drying capabilities at its formulation development and clinical trial manufacturing facility in Garnet Valley, PA.

In this latest U.S. expansion, Quotient Sciences has completed the installation of a GEA Niro Mobile Minor™ unit to support the rapid development of solid dispersions and clinical production of batches sizes up to 10 kg.

Over the past 20 years, Quotient Sciences has built a strong reputation for addressing complex solubility and bioavailability challenges with a range of formulation technologies including spray drying, hot melt extrusion, lipidic systems, and micronization. Small-scale and pilot-scale spray drying has been a core capability in the Company's portfolio of services in the U.K. and in 2017, the company established spray drying in the U.S. with the installation of a ProCepT spray dryer.   

“Our investment in spray drying is in direct response to increasing client demand and the prevalence of poorly soluble molecules in their drug development pipelines,” said Mark Egerton, CEO of Quotient Sciences. “With spray drying expertise on both sides of the Atlantic, we’re now able to seamlessly support our global client base as they transition from preclinical to proof-of-concept patient trials.”

The 45,000-square-foot Garnet Valley site is a hub for early-phase formulation development and clinical trial manufacturing. The facility was designed to handle highly potent products with six high-potency GMP manufacturing suites. Quotient Sciences' expertise in handling highly potent molecules encompasses more than 300 Category 3 - 5 compounds across its manufacturing sites.

Globally, Quotient Sciences has more than 800 employees across six operating sites in the U.K. and U.S., serving a global customer base of more than 150 biotech and pharma clients.